Related Experiment Video
Updated: Apr 23, 2026

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection
Karen B Jacobson1, Maqdooda Merchant1, Bruce Fireman1
1Kaiser Permanente Vaccine Study Center, Oakland, California.
Background:
SARS-CoV-2 vaccination during pregnancy reduces COVID-19 risk in infancy. Whether maternal vaccination before pregnancy similarly protects infants against COVID-19 is unknown.
Methods:
We examined the effectiveness of maternal messenger RNA SARS-CoV-2 vaccination before and during pregnancy in preventing COVID-19 in infants aged 0-6 months born between July 1, 2021, and June 30, 2023, at Kaiser Permanente Northern California. Maternal vaccination status was categorized as vaccinated during pregnancy, during a prepregnancy interval (0-<3, 3-<6, 6-12, and >12 months prepregnancy), or unvaccinated. Secondary analyses examined the effectiveness of vaccination by trimester. COVID-19 was defined by positive SARS-CoV-2 PCR result or diagnostic code, and COVID-19-related hospitalizations were confirmed by medical record review. Vaccine effectiveness (VE) was examined by Cox regression models adjusted for maternal and infant characteristics, calculated as (1 - hazard ratio) × 100%.
Results:
Among 78 644 infants, 3648 (4.6%) had COVID-19 infection and 76 (0.1%) experienced COVID-19-related hospitalization before age 6 months. For the 4 prepregnancy vaccination intervals, estimates for VE against COVID-19 infection ranged from -14.9% (95% CI, -32.8% to 0.5%) for less than 3 months prepregnancy to 23.6% (-14.3% to 49%) for more than 12 months prepregnancy. VE anytime during pregnancy was 7.5% (-2% to 16.2%) against infant COVID-19 infection and 52.9% (11.1%-75.1%) against infant COVID-19-related hospitalization. Effectiveness of third-trimester vaccination was 19.2% (8.6%-28.6%) against infant COVID-19 infection and 64.6% (12.3%-85.7%) against infant COVID-19-related hospitalizations.
Conclusion:
Maternal vaccination during the third trimester was protective against infant COVID-19 infections. Maternal vaccination during pregnancy, particularly during the third trimester, was effective against infant COVID-19-related hospitalizations. Vaccination before pregnancy did not protect infants.
Related Concept Videos
Vaccinations
Teratogenicity
Vaccines
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Cytomegalovirus Disease

